Research programme: muscular dystrophy gene therapies - Columbia University/Sarepta Therapeutics
Alternative Names: AAV gene therapy - Columbia University/ Sarepta TherapeuticsLatest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator Sarepta Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Muscular dystrophies
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Muscular-dystrophies in USA (Parenteral)
- 04 May 2020 Early research in Muscular dystrophies in USA (Parenteral), prior to May 2020 (Sarepta Therapeutics pipeline, May 2020)